TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Low-density Lipoprotein (LDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Repeat medical imaging
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wound healing process
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Willingness to be randomized
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with PTSD defined by PCL-5 score ≥ 31
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-specific orthopaedic surgery model effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986224
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rates of overall antibiotic prescribing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: C-index for predicting major clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who do Not Necessitate a Delay in Standard of Care Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Tumor Infiltrating Lymphocytes (TIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with completed advanced care planning notes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement or worsening in stroke signs/symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with good response to PRRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with no response to PRRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of early complications related to arteriovenous fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of HMR1964 compared to Insulin lispro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of HMR1964 compared to Insulin lispro
Endpoint domain: Adverse events/effects
Primary endpoint: number of pharmacist recommendations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postural Instability and Gait Difficulty Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients undergoing orchiectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0-8 (Area Under the Concentration-time Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of the anticoagulant effect of Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects with a complete radiologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in smoking behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Subjects Abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sleep stability score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinical Global Impression - Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of the first recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Time taken to reach the maximum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wound-infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: GMT ratio of HI antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference between SCRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymph Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant intake within a feeding (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Medication Satisfaction Questionnaire (MSQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Excess Weight Change (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leg Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Action Research Arm Test (ARAT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Primary Liver Graft Nonfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants According to the Severity of BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Need HOT at Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of malignant pulmonary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radiological detection of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Treatment Success at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The lowest SpO2 observed during airway management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enzyme-linked immunosorbent assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mechanical and Heat Hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corsi Block task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Adverse Events Included in the Pre-specified Composite
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Higher Dosage of DHA
Endpoint domain: Adverse events/effects
Primary endpoint: Average Overall Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLT within 7 days of FCN-437c monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: DLT within 28 days of FCN-437c monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: DLT within 28 days of FCN-437c combined therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Nodes Identified by Indocyanine Green (ICG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline 10 meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With NNRTI-Resistant Variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of circulating omega-3 fatty acid (ALA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of time spent with oxygen saturation levels in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Cessation of Status Epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Critical closing pressure of the airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Otoacoustic Suppression Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Half-Life (T 1/2) of SSP-004184
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in CD3 positive T cells in the airway submucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of acne relapse during maintenance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum severity of acne relapse during follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events associated with XYF19 CAR-T cells
Endpoint domain: Adverse events/effects
Primary endpoint: percent forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline Fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline of Glycated hemoglobin A (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Quality of Life Assessed by SF-36v2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proliferative index (Ki67)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Grade 3 or Higher Adverse Events Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Adverse Events Causing Discontinuation of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Health Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Late Parasitological Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as measured by NCI common toxicity table
Endpoint domain: Adverse events/effects
Primary endpoint: Bloating score 1 hour after the colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of adjuvant Sutent therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of absence of deep infection at fracture site and absence of secondary procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in the SF-36v2 PCS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients achieving more than or equal to 5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving more than or equal to 5 cm waist circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: scores on psychometric scales for Generalized Anxiety Disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First variceal bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in retinal morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in beta-islet cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative WBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: migration of acetabulum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scar assessment using Modified Vancouver Scar Scale (MVSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: high sensitivity C-reactive protein Area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity index of facial telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pCLE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum interferon-gamma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ki67 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of opioids consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal colonisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient general health (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to the sepsis protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain scores during bone marrow aspiration and biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of daily OFF-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of hospitalization for intracranial haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of hospitalization for gastrointestinal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of hospitalization for urogenital bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: DNA repair activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Systemic and Local Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of abdominal pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of acute postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in socially adaptive mirroring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Good Root Parallelism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predosage concentration (C0 and C12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sedentary Behavior (Average Hour/Day)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Long-term Potentiation-like Plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography Recordings at Baseline and 5 Minutes Post-PAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Abbreviated Wolf Motor Function Test Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular end-systolic diameter (LVESd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular end-diastolic diameter (LVEDd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ejection fraction of left ventricle (EF LV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of diffuse myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Number of Fluorescein-Stained Epithelial Cells Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Epithelial Cells Collected From Ocular Surface and Contact Lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Viable and Non-Viable Epithelial Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI-related Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular Pacing Capture Threshold (VPCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular Sensing Amplitude (R-wave)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morbidity related to bile duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Difference in SARS-CoV-2 AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality within the first year post kidney transplantation
Endpoint domain: Mortality/survival
Primary endpoint: corneal hysteresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution rate of baseline warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Left Ventricular Global Longitudinal Strain (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraoperative Left Ventricular Global Longitudinal Strain Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The Couple Relationship Skills Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Individual Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relative change of Total Alcohol Consumption (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokines serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Genetic abnormality identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of PCV13 booster vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dry Eye Questionnaire (DEQ-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nonmelanoma skin cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Analgesic (Pethidine) Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion Rate of Chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of recruits with at least one injury
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of residual paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak liking score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 24-hour urinary urea nitrogen (UUN) excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum albumin and prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Secondhand smoke (SHS) exposure of non-smokers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who rate the intervention as helpful
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Midazolam Area Under the Concentration vs. Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Responsiveness Scale, 2nd Edition (SRS-2)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Baseline Heart Rate Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post Exercise Heart Rate Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mortality (No.)
Endpoint domain: Mortality/survival
Primary endpoint: Mortality (%)
Endpoint domain: Mortality/survival
Primary endpoint: Response Rate Defined as the Proportion of Patients With a Best Response of Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival rate of ART occluso-proximal restoration
Endpoint domain: Mortality/survival
Primary endpoint: Survival rate of primary molar after ART restoration
Endpoint domain: Mortality/survival
Primary endpoint: Tendon elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: investigator-reported symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spanish Pain Questionnaire (SPQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Economic Strain Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Depression, Anxiety, and Stress Scale - Stress Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dyadic Coping Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proliferation and differentiation of intestinal MSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline perceived academic stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status